| Germline predisposition to pediatric Ewing sarcoma is characterized by inherited pathogenic variants in DNA damage repair genes R Gillani, SY Camp, S Han, JK Jones, H Chu, S O’Brien, EL Young, ... The American Journal of Human Genetics 109 (6), 1026-1037, 2022 | 27 | 2022 |
| Association of genetic predisposition and physical activity with risk of gestational diabetes in nulliparous women KA Pagel, H Chu, R Ramola, RF Guerrero, JH Chung, S Parry, UM Reddy, ... JAMA network open 5 (8), e2229158-e2229158, 2022 | 12 | 2022 |
| Using Association Rules to Understand the Risk of Adverse Pregnancy Outcomes in a Diverse Population H Chu, R Ramola, S Jain, DM Haas, S Natarajan, P Radivojac PACIFIC SYMPOSIUM ON BIOCOMPUTING 2023: Kohala Coast, Hawaii, USA, 3–7 …, 2022 | 4 | 2022 |
| CAGI, the Critical Assessment of Genome Interpretation, establishes progress and prospects for computational genetic variant interpretation methods N Null, S Jain, C Bakolitsa, SE Brenner, P Radivojac, J Moult, S Repo, ... Genome Biology 25 (1), 1-46, 2024 | 3 | 2024 |
| CAGI, the Critical Assessment of Genome Interpretation, establishes progress and prospects for computational genetic variant interpretation methods Genome Interpretation Consortium arXiv e-prints, arXiv: 2205.05897, 2022 | 2 | 2022 |
| Integrative Analysis of Germline Rare Variants in Clear and Non–clear Cell Renal Cell Carcinoma SH Han, SY Camp, H Chu, R Collins, R Gillani, J Park, Z Bakouny, ... European Urology Open Science 62, 107-122, 2024 | 1 | 2024 |
| Interplay of Mendelian and polygenic risk factors in Arab breast cancer patients M Al-Jumaan, H Chu, A Alsulaiman, SY Camp, S Han, R Gillani, ... Genome Medicine 15 (1), 65, 2023 | 1 | 2023 |
| Abstract PO2-27-12: Genomic determinants of benefit to nivolumab (NIVO) plus low dose ipilimumab (IPI) among patients (pts) with hypermutated HER2-negative metastatic breast … R Barroso-Sousa, T Chinsky, T Li, S Reddy, L Emens, B Overmoyer, ... Cancer Research 84 (9_Supplement), PO2-27-12-PO2-27-12, 2024 | | 2024 |
| Abstract P01: Impact of Germline and Somatic ATM Variants in Chronic Lymphocytic Leukemia (CLL): Clinical Implications and Response to PARP Inhibition K Mashima, N Moore, M Mikhaleva, A Petráčková, S Shupe, ... Blood Cancer Discovery 5 (2_Supplement), P01-P01, 2024 | | 2024 |
| Critical assessment of genome interpretation consortium. CAGI, the critical assessment of genome interpretation, establishes progress and pprospects for computational genetic … S Jain, C Bakolitsa, EB Steven, P Radivojac, J Moult, S Repo, AH Roger, ... Genome Biology 22 (22; 25 (1): 53.), 1-46, 2024 | | 2024 |
| Profiling of Pharmacogenomic Variants in CYP2D6 and DPYD in Indigenous Arab Breast Cancer Patients A Alsulaiman, H Chu, M Al-Jumaan, M Alyahya, YA Marzooq, F Almulhim, ... Pharmacogenomics 24 (7), 411-423, 2023 | | 2023 |
| Patient-partnered research enables germline characterization of angiosarcoma predisposition genes H Chu, M Hollyer, S Han, SY Camp, R Gillani, E Van Allen, N Wagle, ... Cancer Research 83 (7_Supplement), 6064-6064, 2023 | | 2023 |
| Low-pass Whole Genome Imputation Enables the Characterization of Polygenic Breast Cancer Risk in the Indigenous Arab Population M Al-Jumaan, H Chu, A Al-Sulaiman, SY Camp, S Han, R Gillani, ... medRxiv, 2022.12. 07.22282785, 2022 | | 2022 |
| Characteristics of Rare Germline ATM Variants in Chronic Lymphocytic Leukemia (CLL) K Mashima, BL Lampson, A Gupta, N Moore, A Petrackova, SJ Shupe, ... Blood 140 (Supplement 1), 9853-9854, 2022 | | 2022 |
| Patients with Deleterious Germline Variants in STXBP2 Develop Toxicity after CAR-T Cell Therapy with Axicabtagene Ciloleucel MB Leick, S Han, KME Gallagher, H Silva, G Martin, S Camp, H Chu, ... Blood 140 (Supplement 1), 646-647, 2022 | | 2022 |
| PB1163 - Multi-modal characterization of ultra-rare germline genetic variants driving breast cancer risk in the indigenous Arab population H Chu, A Al-Sulaiman, M Al-Jumaan, S Han, SY Camp, R Gillani, ... The Annual Meeting of The American Society of Human Genetics, October 26 …, 2022 | | 2022 |
Saud AlDubayan, MDDana-Farber Cancer Institute | Harvard Medical School | Broad Institute of MIT and HarvardVerified email at dfci.harvard.edu
